TrialFind
Search
About
Saved trials
Back to results
Completed
Phase 4
Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
NCT02948777
What is this trial?
Generating plain-language summary...
Am I eligible?
Generating eligibility summary...
What's involved?
Summarizing study design...
Where and how to apply
Primary location
Helsinki University Hospital, Biomedicum 2U
Helsinki, Finland
View on ClinicalTrials.gov
Official details
Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes — TrialFind